Melatonin is a promising candidate for diabetes therapy because of its antioxidant, anti-inflammatory, and antiapoptotic properties. Melatonin could enhance the effectiveness of other diabetes treatments, particularly when combined with regenerative treatments such as mesenchymal stem cell (MSC) therapies. The pancreas plays a critical role in nutrient digestion and metabolism, and damage to its enzyme-producing cells can lead to malnutrition and a reduced quality of life. Melatonin, a hormone increasingly recognised for its involvement in glucose homeostasis and insulin regulation, has potential in diabetes treatment. The therapeutic potential of melatonin in diabetes underscores the necessity for extensive clinical studies to confirm its efficacy in human populations. Additionally, examining the genetic and environmental factors that may influence individual responses to melatonin therapy could significantly enhance its personalised application in diabetic care. These findings emphasise the need for innovative treatments and suggest that melatonin could improve pancreatic health and quality of life in individuals with diabetes. While melatonin offers protective and restorative benefits, further research is necessary to fully understand its mechanisms and maximise its therapeutic potential.
Author (s) Details
Arunim
Department of Biosciences and Biotechnology, Banasthali Vidyapith,
Banasthali-304022, Rajasthan, India.
Surabhi Bajpai
Department of Biosciences and Biotechnology, Banasthali Vidyapith, Banasthali-304022,
Rajasthan, India.
Please see the book here:- https://doi.org/10.9734/bpi/aodhr/v2/5577
No comments:
Post a Comment